PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28806841-9	2017	Results Variations in two SNPs, rs2888586 (SOS1) and rs2069502 (CDK4), and the GHR exon 3 deletion were significantly associated with response to rhGH treatment.	rhgh	146-150	SOS Ras/Rac guanine nucleotide exchange factor 1	Homo sapiens	43-47
28806841-9	2017	Results Variations in two SNPs, rs2888586 (SOS1) and rs2069502 (CDK4), and the GHR exon 3 deletion were significantly associated with response to rhGH treatment.	rhgh	146-150	cyclin dependent kinase 4	Homo sapiens	64-68
28806841-9	2017	Results Variations in two SNPs, rs2888586 (SOS1) and rs2069502 (CDK4), and the GHR exon 3 deletion were significantly associated with response to rhGH treatment.	rhgh	146-150	growth hormone receptor	Homo sapiens	79-82
24006181-3	2014	At high rhGH concentrations (500 ng/ml), IGF-1 was downregulated, while low concentrations (5 ng/ml) caused IGF-1 upregulation.	rhgh	8-12	insulin like growth factor 1	Homo sapiens	41-46
25080462-8	2014	With rhGH, the intestinal absorption of leucine and glutamine increased (P = 0.036) and correlated with serum insulin (r = 0.91, P = 0.002).	rhgh	5-9	insulin	Homo sapiens	110-117
20462597-16	2011	Following administration of rhGH to HAL rats, the expression of VEGF, VEGFR-2, VEGFR-3, IGF-1R, and GHR was significantly higher (P < 0.05).	rhgh	28-32	vascular endothelial growth factor A	Rattus norvegicus	64-68
20462597-16	2011	Following administration of rhGH to HAL rats, the expression of VEGF, VEGFR-2, VEGFR-3, IGF-1R, and GHR was significantly higher (P < 0.05).	rhgh	28-32	kinase insert domain receptor	Rattus norvegicus	70-77
20462597-16	2011	Following administration of rhGH to HAL rats, the expression of VEGF, VEGFR-2, VEGFR-3, IGF-1R, and GHR was significantly higher (P < 0.05).	rhgh	28-32	Fms related receptor tyrosine kinase 4	Rattus norvegicus	79-86
20462597-16	2011	Following administration of rhGH to HAL rats, the expression of VEGF, VEGFR-2, VEGFR-3, IGF-1R, and GHR was significantly higher (P < 0.05).	rhgh	28-32	insulin-like growth factor 1 receptor	Rattus norvegicus	88-94
20462597-16	2011	Following administration of rhGH to HAL rats, the expression of VEGF, VEGFR-2, VEGFR-3, IGF-1R, and GHR was significantly higher (P < 0.05).	rhgh	28-32	growth hormone receptor	Rattus norvegicus	100-103
21426642-10	2011	The rhGH-treated asthma group demonstrated significantly decreased perforin (0.48 +- 0.08 vs 0.63 +- 0.08; P<0.05) and GzmB (0.44 +- 0.13 vs 0.71 +- 0.15; P<0.05) expression in the lungs compared with the untreated asthma group.	rhgh	4-8	granzyme B	Rattus norvegicus	122-126
17596983-7	2007	The in vivo experiments showed that the rhGH treatment significantly reversed the elevated MDA, ChAT, AChE, and the decreased GSH, ACh levels in the Abeta model mice.	rhgh	40-44	choline acetyltransferase	Mus musculus	96-100
18841527-2	2009	The aim of the present study was to investigate the effects of recombinant human growth hormone (rhGH) and/or testosterone on muscle MGF/IGF-IEa/myostatin expression in intact and hypophysectomized rats treated for 15 d with 1) saline or rhGH, 2) sesame oil or testosterone, 3) saline+sesame oil, or rhGH+testosterone (first experiment) or for 7 d with saline or rhGH (second experiment).	rhgh	97-101	growth hormone 1	Homo sapiens	81-95
18841527-2	2009	The aim of the present study was to investigate the effects of recombinant human growth hormone (rhGH) and/or testosterone on muscle MGF/IGF-IEa/myostatin expression in intact and hypophysectomized rats treated for 15 d with 1) saline or rhGH, 2) sesame oil or testosterone, 3) saline+sesame oil, or rhGH+testosterone (first experiment) or for 7 d with saline or rhGH (second experiment).	rhgh	97-101	insulin like growth factor 1	Homo sapiens	133-136
17596983-7	2007	The in vivo experiments showed that the rhGH treatment significantly reversed the elevated MDA, ChAT, AChE, and the decreased GSH, ACh levels in the Abeta model mice.	rhgh	40-44	acetylcholinesterase	Mus musculus	102-106
17596983-7	2007	The in vivo experiments showed that the rhGH treatment significantly reversed the elevated MDA, ChAT, AChE, and the decreased GSH, ACh levels in the Abeta model mice.	rhgh	40-44	amyloid beta (A4) precursor protein	Mus musculus	149-154
34737778-0	2021	Analysis of the Influence of High-Dose rhGH Therapy on Serum Vitamin D and IGF-1 Levels in School-Age Children with Idiopathic Short Stature.	rhgh	39-43	insulin like growth factor 1	Homo sapiens	75-80
12906752-5	2003	Serum IGF-I levels in Hpx rats after the injection of rhGH-SR2W microcapsules were higher than those after daily injections of rhGH solution.	rhgh	54-58	insulin-like growth factor 1	Rattus norvegicus	6-11
10556788-4	1999	In non-pregnant rats treated with rhGH for 3 days, serum IGF-I concentrations (835.4+/-59.5 ng/ml; P<0.01) were significantly greater than in those animals treated with saline (319.6+/- 95.6 ng/ml).	rhgh	34-38	insulin-like growth factor 1	Rattus norvegicus	57-62
12054120-8	1999	During the hyperinsulinemic clamp which raised plasma insulin levels to 7.2 +/- 0.4 ng/ml, HGO was suppressed in the control and rhGH+T treated rats but not in the rats treated with rhGH and rhGH+DCI.	rhgh	129-133	insulin	Homo sapiens	16-23
9589675-6	1998	Although rates of baseline hepatic glucose production, GF, and GS were unchanged, the insulin-stimulated increment (delta) in Rd, GF, and GS remained markedly attenuated in the long-term rhGH-treated GHD adults [pretreatment: delta Rd 16.6 +/- 3.4, delta GF 3.0 +/- 1.2, delta GS 13.6 +/- 3.0 vs. 24 months of rhGH: delta Rd 17.2 +/- 3.3, delta GF 3.1 +/- 0.9, delta GS 14.1 +/- 2.5 vs. controls: delta Rd 42.6 +/- 4.3, delta GF 9.2 +/- 1.9, delta GS 35.9 +/- 4.5 mumol/kg fat free mass.min; P < 0.05-0.01 vs. controls].	rhgh	187-191	insulin	Homo sapiens	86-93
9695731-13	1998	Hepatic tissue HGF concentrations were higher in non-rhGH-treated rats compared to rhGH treated animals 7 days after burn (P < 0.01).	rhgh	53-57	hepatocyte growth factor	Rattus norvegicus	15-18
34723984-0	2021	Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy: LG growth study database.	rhgh	109-113	insulin like growth factor 1	Homo sapiens	28-33
12161519-12	2002	Injection of rhGH attenuated subsequent GHRH-stimulated peak serum GH concentrations (micrograms per liter) to 7.8 +/- 1.9 (PP), 5.8 +/- 1.2 (MP), and 4.8 +/- 1.1 (YM) (each P < 0.01 vs. saline; P = NS pubertal effect).	rhgh	13-17	growth hormone releasing hormone	Homo sapiens	40-44
9186821-6	1997	Administration of rhGH (250 micrograms/kg/twice daily, sc) induced a significant inhibition of GHRH and a significant stimulation of SRIF mRNA levels in C rats; GH treatment was, however, ineffective on both neuropeptide mRNA levels in the S group.	rhgh	18-22	growth hormone releasing hormone	Rattus norvegicus	95-99
8995031-5	1996	A significant increase in insulin-like growth factor I (IGF-I) was observed in the rhGH-treated group (200 to 527ng/ml, p = 0.01), while a decrease was noticed in the placebo group (285 to 219ng/ml, p = 0.02).	rhgh	83-87	insulin like growth factor 1	Homo sapiens	26-54
8995031-5	1996	A significant increase in insulin-like growth factor I (IGF-I) was observed in the rhGH-treated group (200 to 527ng/ml, p = 0.01), while a decrease was noticed in the placebo group (285 to 219ng/ml, p = 0.02).	rhgh	83-87	insulin like growth factor 1	Homo sapiens	56-61
7545763-9	1995	A significant correlation between IGF-1 and IGFBP-3 levels is present in the trauma patients who received TPN and rhGH.	rhgh	114-118	insulin like growth factor 1	Homo sapiens	34-39
7545763-9	1995	A significant correlation between IGF-1 and IGFBP-3 levels is present in the trauma patients who received TPN and rhGH.	rhgh	114-118	insulin like growth factor binding protein 3	Homo sapiens	44-51
31658543-24	2019	The mass concentration of serum IgA and complement C3 of children in group rhGH on the 3rd and 7th day of rhGH treatment was significantly higher than that before rhGH treatment(P<0.05).	rhgh	75-79	complement C3	Homo sapiens	40-53
33982678-12	2021	Conclusions: The combination of peak GH to GH stimulation testing and baseline IGF-I concentration are predictive enrichment markers for annualized HV responses to rhGH therapy.	rhgh	164-168	insulin like growth factor 1	Homo sapiens	79-84
32509520-9	2020	Nevertheless, the protein expression of hepatic IGF-1 was markedly increased by FO 100 and rhGH administration.	rhgh	91-95	insulin like growth factor 1	Homo sapiens	48-53
32847563-7	2020	CONCLUSIONS: This is the first case of GHD in a Caucasian boy with GLUT1DS diagnosed before starting ketogenic diet, with a good response to rhGH treatment and absence of side effects.	rhgh	141-145	solute carrier family 2 member 1	Homo sapiens	67-74
31658543-14	2019	(2) The percentages of CD4(+) T lymphocytes of children in group rhGH before rhGH treatment and on the 7th day of rhGH treatment were (35.1+-2.0)% and (38.5+-2.2)%, which were close to (36.2+-2.0)% and (33.6+-2.2)% in control group, respectively (t=0.371, 1.553, P>0.05).	rhgh	65-69	CD4 molecule	Homo sapiens	23-26
31658543-16	2019	The percentage of CD4(+) T lymphocytes of children in group rhGH on the 7th day of rhGH treatment was significantly higher than that before rhGH treatment (P<0.05).	rhgh	60-64	CD4 molecule	Homo sapiens	18-21
31658543-16	2019	The percentage of CD4(+) T lymphocytes of children in group rhGH on the 7th day of rhGH treatment was significantly higher than that before rhGH treatment (P<0.05).	rhgh	83-87	CD4 molecule	Homo sapiens	18-21
31658543-17	2019	The percentages of CD4(+) T lymphocytes of children in control group on the 3rd and 7th day of rhGH treatment were both close to the percentage before rhGH treatment (P>0.05).	rhgh	95-99	CD4 molecule	Homo sapiens	19-22
31658543-18	2019	(3) The percentage of CD8(+) T lymphocytes of children in group rhGH on the 3rd day of rhGH treatment was significantly lower than that in control group (t=2.107, P<0.05).	rhgh	64-68	CD8a molecule	Homo sapiens	22-25
31658543-18	2019	(3) The percentage of CD8(+) T lymphocytes of children in group rhGH on the 3rd day of rhGH treatment was significantly lower than that in control group (t=2.107, P<0.05).	rhgh	87-91	CD8a molecule	Homo sapiens	22-25
31658543-20	2019	The ratio of CD4(+) T lymphocytes to CD8(+) T lymphocytes of children in group rhGH on the 7th day of rhGH treatment was significantly higher than 2.04+-0.19 before rhGH treatment (P<0.05).	rhgh	79-83	CD4 molecule	Homo sapiens	13-16
31658543-20	2019	The ratio of CD4(+) T lymphocytes to CD8(+) T lymphocytes of children in group rhGH on the 7th day of rhGH treatment was significantly higher than 2.04+-0.19 before rhGH treatment (P<0.05).	rhgh	79-83	CD8a molecule	Homo sapiens	37-40
31658543-20	2019	The ratio of CD4(+) T lymphocytes to CD8(+) T lymphocytes of children in group rhGH on the 7th day of rhGH treatment was significantly higher than 2.04+-0.19 before rhGH treatment (P<0.05).	rhgh	102-106	CD4 molecule	Homo sapiens	13-16
31658543-20	2019	The ratio of CD4(+) T lymphocytes to CD8(+) T lymphocytes of children in group rhGH on the 7th day of rhGH treatment was significantly higher than 2.04+-0.19 before rhGH treatment (P<0.05).	rhgh	102-106	CD8a molecule	Homo sapiens	37-40
35482097-10	2022	CONCLUSIONS: Increase in height Z-score in the first year post-kTx was highest in the CS - /rhGH - group and lowest in the CS + /rhGH + group.	rhgh	92-96	citrate synthase	Homo sapiens	86-88
35250656-15	2022	Compared with the baseline, the level of serum IGF-1 and IGFBP-3 increased significantly (P < 0.05) following 3-months rhGH treatment, while the placebo group had no significant impact on serum IGF-1 and IGFBP-3 (P > 0.05).	rhgh	119-123	insulin like growth factor 1	Homo sapiens	47-52
35250656-15	2022	Compared with the baseline, the level of serum IGF-1 and IGFBP-3 increased significantly (P < 0.05) following 3-months rhGH treatment, while the placebo group had no significant impact on serum IGF-1 and IGFBP-3 (P > 0.05).	rhgh	119-123	insulin like growth factor binding protein 3	Homo sapiens	57-64
35250656-15	2022	Compared with the baseline, the level of serum IGF-1 and IGFBP-3 increased significantly (P < 0.05) following 3-months rhGH treatment, while the placebo group had no significant impact on serum IGF-1 and IGFBP-3 (P > 0.05).	rhgh	119-123	insulin like growth factor binding protein 3	Homo sapiens	204-211
35093163-6	2022	RESULTS: rhGH administration increased levels of IGF-1 by at least 2 standard deviations and was well tolerated without serious adverse events.	rhgh	9-13	insulin like growth factor 1	Homo sapiens	49-54
35178492-10	2022	Conclusions: SNPs within ZBTB38 associated with ISS are linked to higher birth size within a cohort of ISS patients and a better response to rhGH therapy while ZBTB38 expression is positively related to age.	rhgh	141-145	zinc finger and BTB domain containing 38	Homo sapiens	25-31
33544498-7	2021	CONCLUSION: Intrauterine growth retardation, postnatal growth failure, and IGF-1 resistance during rhGH treatment are homologous features exhibited by affected patients, and may be predictive of IGF1R defects.	rhgh	99-103	insulin like growth factor 1	Homo sapiens	75-80
33544498-7	2021	CONCLUSION: Intrauterine growth retardation, postnatal growth failure, and IGF-1 resistance during rhGH treatment are homologous features exhibited by affected patients, and may be predictive of IGF1R defects.	rhgh	99-103	insulin like growth factor 1 receptor	Homo sapiens	195-200
33205215-8	2021	rhGH treatment significantly improved the height SDS of patients with NPR2 heterozygous mutation (median -2.1 vs -2.9, P<0.001), especially in girls.	rhgh	0-4	natriuretic peptide receptor 2	Homo sapiens	70-74
31658543-24	2019	The mass concentration of serum IgA and complement C3 of children in group rhGH on the 3rd and 7th day of rhGH treatment was significantly higher than that before rhGH treatment(P<0.05).	rhgh	106-110	complement C3	Homo sapiens	40-53
30908679-7	2019	Plasma IGF-I concentrations rose in both groups with rhGH stimulation (P < 0.0001).	rhgh	53-57	insulin like growth factor 1	Homo sapiens	7-12
30908679-9	2019	Further, the increase in insulin concentrations in response to rhGH stimulation was ~3-fold greater in NS children (142% vs 50%; P = 0.006).	rhgh	63-67	insulin	Homo sapiens	25-32
30908679-11	2019	Thus, the lower IGF-I response to rhGH stimulation in association with decreasing birthweight indicates that the ISS children at the lower end of the birthweight spectrum may have partial GH resistance, which may contribute to their poorer growth.	rhgh	34-38	insulin like growth factor 1	Homo sapiens	16-21